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Abstract
Background: PorA, fetA and fHbp are three antigen encoding genes useful for meningococcal typing and FHbp is
an important component of meningococcal B vaccines.
Methods: We performed sequence analysis of meningococcal porA, fetA and fHbp genes on 128 isolates from
Western Australia, relating results to age, gender, race and geographic region.
Results: We found predominantly PorA subtypes P1.22,14-16 (n = 23) and P1.7-2,4 (n = 19); FetA subtypes F1-5
(n = 41), F3-6 (n = 11), F5-1 (n = 10), F5-2 (n = 9), F5-5 (n = 8), F3-3 (n = 8); and FHbp variant groups 1 (n = 65) and 2
(n = 44). PorA P1.22,14-16 and FHbp variant group 2 were associated with younger age and aboriginality.
Conclusions: FHbp modular groups of the bivalent recombinant FHbp vaccine and the multicomponent 4CMenB
vaccine make up 8.3% and 47.7% respectively of the examined serogroup B isolates from 2000–2011, however to
estimate vaccine efficacy requires an account of all vaccine antigens and their levels of expression.
Keywords: Neisseria meningitidis, Factor H binding protein, PorA, FetA, Meningococcal epidemiology,
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Background
Invasive meningococcal infection is a rapidly progressing
disease with a case fatality rate of 10% and 10-20% of
survivors experience serious permanent sequelae. Of the
12 Neisseria meningitidis serogroups, the majority of in-
vasive disease is caused by serogroups A, B, C, Y and W.
Serogroup B, C and Y are responsible for most infections
in North America and Europe, while serogroup A con-
tinues to cause major epidemics in sub-Saharan Africa
[1]. Western Australia is a highly multicultural popula-
tion of 2.4 million people living in an area greater than
2.5 million square kilometres encompassing tropical and
temperate climatic zones, factors which would predict
meningococcal strain variability. However the level of
urbanisation should be appreciated with 78% of the
population residing within the greater area of the capital
city, Perth [2]. For informing public health responses,
meningococcal typing is performed by sequencing antigen
encoding genes such as factor H binding protein (fHbp),
variable regions of porA and fetA, and by multilocus se-
quence typing (MLST). The seven housekeeping genes
analysed by MLST are under stabilising selection making
the technique useful for tracking long-term national and
international epidemiology [3]. PorA is a porin that is a
major constituent of the outer membrane of most menin-
gococcal isolates and contains two major variable regions
(VR1 and VR2), designated in short form as P1.VR1,VR2.
Currently there are 249 unique peptide sequences grouped
into 10 families reported for VR1, with 694 unique peptide
sequences grouped into 20 VR2 families [4]. FetA is an
iron-regulated meningococcal outer membrane protein,
with 417 unique variable region peptides categorised into
nine families, F1 to F9 [4]. Factor H is a human factor that
inhibits the alternative complement pathway which, when
bound to the meningococcal cell surface by the Factor H
binding protein (FHbp), leads to impaired human comple-
ment activation and reduced microbial killing [5]. The
classification of FHbp is complicated by multiple overlap-
ping nomenclature schemes. Fletcher et al. [6] classified
FHbp into subfamilies A and B and Masignani et al. [7]
into variant groups 1 (corresponding to subfamily B), 2 and
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3 (together corresponding to subfamily A). More recently,
modular groups I-IX have been assigned based on differ-
ent combinations of either variant group 1 or 3 peptide
types in five modular segments (A, B, C, D, E). Brehony
et al. [8] proposed an alternative nomenclature scheme
assigning a number to each distinct fHbp allele or peptide.
The numbers are arbitrary being assigned sequentially to
new alleles/peptides.
The development of a broadly protective meningococcal
B vaccine is proving a formidable challenge. The meningo-
coccal B polysaccharide is an autoantigen expressed by a
number of host tissues and, as such is not a vaccine
candidate due to poor immunogenicity. The detergent-
extracted outer membrane vesicle (OMV) vaccines are
most active against certain strains because the serum bac-
tericidal antibody (SBA) responses are largely directed
against PorA protein, which is antigenically highly variable
and poorly cross reactive [9]. Likewise the vaccine poten-
tial of FetA has been limited by antigenic variability [10].
In contrast, broad serogroup B meningococcal immunity
is possible with recombinant FHbp vaccines as antibodies
generated against FHbp subfamily A strains have cross
immunity to other subfamily A types, and antibodies
against FHbp subfamily B strains have cross immunity to
other subfamily B types [9,11]. The bivalent recombinant
vaccine manufactured by Pfizer containing FHbp subfam-
ily A and B variants (subfamily A strain is variant group 3,
Brehony peptide 45, and subfamily B strain is variant
group 1, Brehony peptide 55) is well tolerated in adoles-
cents and toddlers and induces robust SBA responses
against a selection of serogroup B strains [12,13]. The sec-
ond major meningococcal B vaccine (4CMenB) manufac-
tured by Novartis contains an FHbp subfamily B variant
(variant group 1, peptide 1) in combination with the men-
ingococcal antigens neisserial adhesin A (NadA), neisserial
heparin-binding antigen (NHBA), and an OMV from the
New Zealand outbreak strain NZ98/254. It also appears to
be well tolerated and immunogenic against the serogroup
B strains tested [14,15] and was registered by the Thera-
peutic Goods of Australia 14 August 2013, but predicted
efficacy of the vaccines will depend on knowledge of local
circulating FHbp, NadA, NHBA, and PorA types and the
expression of these antigens [16,17]. This study was there-
fore undertaken to describe the distribution of meningoc-
cocal PorA, FetA and FHbp types in Western Australia
and provide information to help predict the likelihood of
meningococcal B vaccine efficacy in our region.
Methods
Selection of Neisseria meningitidis isolates
Between 1 January 2000 and 31 December 2011, 497 cases
of invasive meningococcal disease (mandatory notification
is required in Western Australia) were notified to the
Communicable Disease Control Directorate (CDCD), the
central public health unit of Western Australia. We tested
128 isolates of the 271 cases which had a stored meningo-
coccal culture isolate. A confirmed invasive meningococ-
cal case requires isolation of N. meningitidis or detection
of specific meningococcal DNA sequences by nucleic acid
amplification testing from a normally sterile site; or clin-
ical evidence of disease (an illness deemed compatible
with meningococcal disease by the treating physician) with
suggestive laboratory evidence such Gram negative diplo-
cocci seen on microscopy from a sterile site. Also notified
are probable cases defined by a clinically compatible ill-
ness including haemorrhagic rash or a close contact with
a confirmed case within the previous 60 days, with no evi-
dence for other causes of the clinical condition [18]. The
statewide policy is to send a subculture from all invasive
meningococcal cases to the state meningococcal labora-
tory at the Princess Margaret Hospital for Children
(PMH). Isolates were not available for all notified cases
due to culture negative meningococcal diagnoses by nu-
cleic acid detection (125 cases), strain loss and solely clin-
ical diagnoses. The 128 meningococcal isolates examined
were those isolates stored only at PMH rather than add-
itionally at the meningococcal culture collection of the
large Western Australian public laboratory at the Queen
Elizabeth II Medical Centre. The number of isolates (per-
centage of notified cases) tested from each year is as fol-
lows; 2000: 21 (24.4%), 2001: 24 (32.4%), 2002: 13 (19.4%),
2003: 10 (21.7%), 2004: 13 (32.5%), 2005: 12 (25.5%), 2006:
6 (28.6%), 2007: 3 (15.0%), 2008: 9 (37.5%), 2009: 12
(42.8%), 2010: 1 (4.5%), 2011: 4 (18.2%). In addition to the
demographic data of age, sex and geographic region of
residence, we recorded aboriginality, survival and the ana-
tomical site of the isolate. Isolates were serogrouped with
Remel monovalent agglutinating sera (Thermo Scientific
Remel, Lenexa, KA, USA).
Polymerase chain reaction (PCR) and sequencing
Isolates were stored at −80°C in tryptic soy broth con-
taining 15% glycerol. After thawing and culture, several
colonies on chocolate blood agar were placed in 10% sa-
line and heated to 70°C for one hour exposing the DNA.
The nested PCR primers of Table 1 were designed using
GenBank sequences [19], to target conserved regions of
the porA, fetA and fHbp genes (accession numbers in
Additional file 1: Table S5). Faint or no bands on gel
electrophoresis were obtained with single step PCR tech-
niques leading to the use of nested PCR reactions. We
chose to design primers believing they may perform su-
periorly to some published primers based on homology
to a greater proportion of GenBank sequences. Because
at initial planning the chosen portion of the fetA gene
looked too long for a single sequence, we amplified two
overlapping gene segments (overlap not in the variable
region), and we needed to use an alternate reverse
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primer to obtain a complete fHbp sequence for six iso-
lates (J42, K25, K41, K113, K276, P601-further details
regarding these isolates are found Additional file 1:
Table S6). Sequencing primers were the same as sec-
ond round primers.
First round PCR reactions (20 μL total volume) com-
prised 8 μL of sample and 12 μL of mix containing
0.2 μmol/L of each deoxynucleotide triphosphate (dNTP),
1.5 mmol/L of MgCl2, 0.5 units of AmpliTaq Gold DNA
polymerase (Applied Biosystems, Foster City, CA, USA),
0.2 μmol/L of both forward and reverse primer, 0.01% bo-
vine serum albumin, 2 μL of buffer PE (Qiagen, Valencia,
CA, USA) and 8.424 μL of H2O. PCR was conducted with
an initial 10 minutes at 95°C, followed by 45 cycles of de-
naturation at 94°C for 30 seconds, annealing at 55°C for
30 seconds, and extension at 72°C for 60 seconds; after
which there was 1 cycle of 72°C for 7 minutes, then hold-
ing at 4°C. Second round PCR reactions (20.5 μL total
volume) comprised 0.5 μL of 1st round PCR product and
20 μL of mix containing 0.2 μmol/L for each dNTP,
2 mmol/L MgCl2, 0.5 units of AmpliTaq Gold DNA poly-
merase, 0.2 μmol/L of both forward and reverse primer,
0.01% bovine serum albumin, 2.04 μL of buffer PE (Qiagen)
and 15.946 μL of H2O. We performed PCR with the same
conditions as the 1st round PCR.
Second round product was detected by 2.5% ethidium
bromide gel electrophoresis and clean up of this product
was accomplished with Exo SAP-IT (USB Corporation,
Cleveland, OH, USA).
Sequencing reactions (total volume 10 μL) comprised
2.5 μL of cleaned 2nd round PCR product, and 7.5 μL of
mix containing 1 μL of Big Dye Terminator 3.1 reaction
mix (Applied Biosystems), 1.5 μL of Big Dye Terminator
5x buffer, 3.2 μL (0.43 μmol/L) primer and 1.8 μL H2O.
We performed 45 cycles of denaturation at 95°C for
10 seconds and annealing/extension at 60°C for 30
seconds, followed by holding at 4°C. Sequencing product
was centrifuged into 20 μL of formamide via DyeEx 2.0
spin kit filters (Qiagen, Valencia, CA, USA) and analysed
in the ABI 3130xI DNA sequencer (Applied Biosystems).
We sequenced in the forward and reverse direction to
improve accuracy. All PCR and sequencing reactions
were performed using ABI 2720 thermocyclers (Applied
Biosystems).
Bioinformatic analysis
Sequences were examined in BioEdit version 7.1.3 [20]
and were aligned by CLUSTAL W [21]. PorA, FetA and
FHbp types were determined by importing nucleotide
sequences at the Neisseria Sequence Typing home page
[4]. Our sequences contained FHbp modular segments
A, B, C, D akin to many prior FHbp studies. Lacking
modular segment E meant FHbp allele identification were
“closest hits”. Continuous variables were examined by
Mann Whitney U test and categorical variables by Chi-
squared test or Fisher’s exact test as appropriate. Statistics
including logistic and multiple regression were performed
in MedCalc version 12.4.0.0. A two-sided p value of <0.05
was used to indicate statistical significance.
Ethical considerations
We characterised isolates submitted as a component of
the mandatory reporting of invasive meningococcal dis-
ease cases according to the Western Australian Health
Act [22]. Human Research Ethics Committee review
was not required as the research is of negligible risk
and conforms to section 5.1.18-5.1.21 of the Australian




We examined isolates from 128 cases with a mean age
of 4.6 years (range 0.09 to 90.8 years) and 74 were male
and 54 female. Twenty (15.9% of 126 cases where race
was known) were aboriginal comparing to 3.8% aborigi-
nality of the Western Australian population [24]. There
Table 1 Primers for porA, fetA and fHbp PCR reactions
Primer Sequence (5′-3′)
porA 1st round forward primer 5′-AAA CTT ACC GCC CTC GTA-3′
porA 1st round reverse primer 5′-TTA GAA TTT GTG GCG CAA ACC GAC-3′
porA 2nd round forward primera 5′-CCG CAC TGC CGC TTG CGG-3′
porA 2nd round reverse primera 5′-CGC ATA TTT AAA GGC ATA-3′
fetA (segment 1) 1st round
forward primerb
5′-CGG CGC MAG CGT ATT CGG-3′
fetA (segment 1) 1st round
reverse primerc
5′-GCG GTT TGA TTT CCT GAT GG-3′
fetA (segment 1) 2nd round
forward primera
5′-TTR TTC TCT TAC AAC CGC ARC-3′
fetA (segment 1) 2nd round
reverse primera,c
5′-GCG GTT TGA TTT CCT GAT GG-3′
fetA (segment 2) 1st round
forward primer
5′-GCC TTG CCG AAC AAA CYC-3′
fetA (segment 2) 1st round
reverse primer
5′-CGC CCA ATT CGT AAC CGT-3′
fet A (segment 2) 2nd round
forward primera
5′-TCA ACT ACC GCC ATC AGG A-3′
fetA (segment 2) 2nd round
reverse primera
5′-TTT GAT GGT YTG CCA RAA GTA GC-3′
fHbp 1st round foward primer 5′-GTG AAY CGA ACT RCC TTC TRY-3′
fHbp 1st and 2nd round
reverse primera
5′-TGT TCR ATT TTG CCG TRY-3′
5′-TGG TIT TTT TYA TCC GGC TTR-3′
fHbp 2nd round forward primera 5′-CCC TGA TTC TGA CCG CCT G-3′
aSecond round primers also used as sequencing primers.
bS1 primer from Thompson et al. [12].
cS4 primer from Thompson et al. [12].
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were 104 cases from metropolitan Perth, 20 from re-
gional Western Australia, and one each from interstate
and overseas (2 cases from unknown region). Isolates were
predominately of serogroup B (n = 109) and C (n = 15),
with only 2 isolates each of serogroup W and Y. Isolate
serogroup by year was; 2000: 17 B (85.0%), 3 C (15.0%),
2001: 20 B (83%), 3 C (12.5%), 1 W (4.2%), 2002: 10 B
(71.4%), 4 C (28.6%), 2003: 11 B (100%), 2004: 9 B (75.0%),
2 C (16.7%), 1 W (8.3%), 2005: 12 B (100%), 2006: 5 B
(83.3%), 1 C (16.7%), 2007: 3 B (100%), 2008: 9 B (100%),
2009: 9 B (75.0%), 2 C (16.7%), 1 Y (8.3%), 2010: 1 B
(100%), 2011: 3 B (75.0%), 1 Y (25.0%).
We analysed how representative the 128 selected cases
were of all 497 reported invasive meningococcal cases
over the time period. A similar proportion of the exam-
ined 128 isolates compared to the 497 cases reported to
the public health department were male (57.8% vs 58.7%,
p = 0.927), aboriginal (16.5% vs 15.9%, p = 1.00) and
serogroup B (85.1% vs 87.1%, p = 0.521), however the se-
lected cases compared to the total cases were significantly
younger (0–4 years old 51.6% vs 41.3%, p = 0.045) and
urbanised (84.4% vs 72%, p = 0.006).
Genotyping results
A porA, fetA and fHbp sequence was obtained for all iso-
lates and while most could be identified (Additional file 1:
Table S6), 32 fetA and 3 fHbp translated sequences
(Additional file 1: Table S7) were treated as no result
which contained a stop codon. PorA P1.22,14-16 (n = 23)
and P1.7-2,4 (n = 19) were the predominant PorA types.
The main FetA types were F1-5 (n = 22), F3-6 (n = 11), F5-
1 (n = 10), F5-2 (n = 9), F5-5 (n = 8) and F3-3 (n = 8). The
predominant FHbp alleles were 654 (n = 28), 733 (n = 17)
and 15 (n = 12). FHbp variant group 1 was most common
(n = 65), followed by group 2 (n = 44) and group 3 (n = 15),
meaning a similar number of subfamily A (n = 60, being
variant group 2 and 3) and B (n = 65, being variant
group 1).
Genotyping association with other variables
Using the main PorA, FetA and FHbp subtypes we
examined for association with patient demographics
(Tables 2, 3 and 4). PorA subtype P1.22,14-16 and FHbp
variant group 2 were both significantly associated with
younger age and a higher proportion of aboriginal cases.
A multivariate logistic regression model of aboriginality
which incorporated P1.22,14-16, FHbp variant group 2
and age, demonstrated FHbp was independently associ-
ated with aboriginality (p = 0.027, regression coefficient
0.164, standard error 0.073). A logistic regression model
of age incorporating P1.22, 14–16, variant group 2 and
aboriginality showed none of these variables were in-
dependently associated with age (p = 0.293, p = 0.052,
p = 0.821 respectively).
The PorA, FetA and FHbp subtypes were evenly repre-
sented through 2000 to 2009 (data not shown). Too few
isolates from 2010 and 2011 were tested to comment on
trends in these latter years. The number of cases was
highest in the third quarter (n = 45) most closely associ-
ated with the winter season, compared to second quarter
(n = 31), fourth quarter (n = 23) and first quarter (n = 23).
Demographic and genotypic data for each isolate are pre-
sented in Additional file 1: Table S6.
Discussion
Since the 1980s invasive meningococcal disease in Australia
has occurred in a hypersporadic pattern with a current rate
(2011) of 0.9 cases per 100,000 population, and the last re-
ported outbreak in Western Australia occurred prior to
1995 [25,26]. There is scant Australian published data re-
garding meningococcal genotypes. The Australian National
Neisseria Network collecting data on invasive meningococ-
cal disease from each state reference laboratory, have only
published PorA typing results of serogroup B isolates from
2010 and 2011, showing the predominant types of P1.7-2,4,
P1.7,16-26 and P1.22,14 [26,27]. Overall P1.22,14-16 and
P1.7-2,4 were the predominant subtypes in our study (we
had 5 of P1.7,16-26 and 7 of P1.22,14) though we exam-
ined very few isolates from 2010 and 2011 making the
comparison difficult. Our PorA typing results suggest the
most prevalent MeNZB OMV strain (P1.7-2,4) in isolation
may provide poor coverage for our local strains, as this
subtype comprised only 15.6% of our meningococcal B
isolates. We found PorA P1.22,14-16 and FHbp variant
group 2 were associated with younger age and a higher
proportion of aboriginal cases. A multivariate logistic re-
gression model of aboriginality which incorporated
P1.22,14-16, FHbp variant group 2 and age, demonstrated
Table 2 Demographic factors related to predominant PorA VR1, VR2 subtypes
P1.22,14-16 Non P1.22,14-16 p value P1.7-2,4 Non P1.7-2,4 p value
Age* 1.32 6.01 <0.005† 6.29 4.33 <0.005†
Male 12 (52.2) 62 (59.0) 0.710 14 (73.7) 60 (55.0) 0.205
Aboriginal 9 (39.1) 11 (10.5) 0.002 0 (0.0) 20 (18.5) 0.089
Regional 7 (30.4) 13 (12.4) 0.065 6 (31.6) 14 (12.8) 0.08
TOTAL 23 105 19 109
Values are numbers (%). *Geometric mean age in years. †p value based on arithmetic means.
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FHbp variant group 2 to be independently associated with
aboriginal cases. However, FHbp being an imperfect
marker of lineage means the observed association could
be due to other characteristics of a lineage in aboriginal
people rather than FHbp itself. Considering meningococ-
cal prevention in the high risk aboriginal population,
FHbp subfamily B of the multicomponent Novartis men-
ingococcal B vaccine made up only 26.3% (5/19) of ser-
ogroup B aboriginal cases. However, the significance of
this finding is unclear as we have not tested for the other
components of the vaccine or gene expression [9].
Consistent with most countries examined apart from
South Africa, we found the percentage of meningococcal
strains carrying FHbp subfamily B variants (53.1%) was
higher than those carrying FHbp subfamily A variants
[28,29]. We found 2 isolates (both serogroup B) precisely
matching the subfamily A and no isolates precisely
matching the subfamily B components of the bivalent
Pfizer vaccine [12]. Regarding this vaccine’s modular and
variant groups, we found 5 modular group V and 4
modular group IV serogroup B isolates (8.26% of ser-
ogroup B isolates), 57 variant group 1 and 14 variant
group 3 serogroup B isolates (65% of serogroup B iso-
lates). There were no isolates precisely matching the
subfamily B FHbp component of the multicomponent
4CMenB Novartis meningococcal B vaccine [30], how-
ever there were 52 modular group I and 57 variant
group 1 serogroup B isolates (47.7% and 52.3% of ser-
ogroup B isolates respectively). If vaccine-induced anti-
FHbp antibodies have highest bactericidal activity against
isolates from a modular group matching the vaccine
strain(s) [31], our data would suggest that the multicom-
ponent Novartis vaccine may provide better overall
coverage of our strains. Determination of the relative
frequencies of NadA and NHBA types are also needed
to predict the multicomponent vaccine efficacy, however
it should be noted that genetic data alone has insuffi-
cient discriminatory power to estimate vaccine coverage.
Further information would be provided by testing our
isolates with the recently described meningococcal anti-
gen typing system (MATS), a method accounting not
only for gene presence but also for the level of antigen
gene expression and cross reactivity, which can be used
to predict strain responsiveness to a vaccine [16,17]. Nis-
sen et al. tested 373 Australian invasive meningococcal
B isolates (including an unreported percentage of isolates
from Western Australia) from 2009–2011 by MATS with
regard to the multicomponent Novartis meningococcal B
vaccine, finding 76% of isolates demonstrated relative po-
tency over the positive bacterial threshold for at least one
antigen vaccine component [32].
Our study looks at three relevant meningococcal
genes, including a key component of meningococcal B
vaccines. It would be interesting to compare our results
to similar data from other parts of Australia and our
region as the antigenic variability we have demonstrated
in Western Australia may be peculiar to our diverse geo-
graphical, climatic and cultural landscape. There is po-
tential for selection bias as we excluded isolates that
were also stored at the Queen Elizabeth II Medical
Centre public laboratory, which although being a site
that receives isolates from a large number of laboratories
statewide, is likely biased towards strains from adult
cases by servicing a large adult tertiary hospital. Indeed
our set were significantly younger and less likely to res-
ide rurally compared to all reported cases. Only five iso-
lates from 2010/2011 were examined leaving us unable
to draw conclusions regarding these years and the inter-
pretation of temporal trends was hampered by the vari-
able percentage of isolates examined per year (range
Table 3 Demographic factors related to predominant FetA subtypes
F1-5 Non F1-5 p value F3-6 Non F3-6 p value F5-1 Non F5-1 p value
Age* 3.65 4.78 0.500† 8.39 4.33 0.255† 5.46 4.51 0.866†
Male 11 (50.0) 63 (59.4) 0.563 5 (45.0) 64 (54.7) 0.786 8 (80.0) 64 (54.2) 0.942
Aboriginal 5 (22.7) 15 (14.1) 0.505 0 (0.0) 20 (17.1) 0.290 1 (10.0) 19 (16.1) 0.955
Regional 7 (31.8) 13 (12.3) 0.048 0 (0.0) 20 (17.1) 0.290 0 (0.0) 20 (17.0) 0.355
TOTAL 22 106 11 117 10 118
Values are numbers (%). *Geometric mean age in years. †p value based on arithmetic means.
Table 4 Demographic factors related to FHbp variant groups
VG1 Non VG1 p value VG2 Non VG2 p value VG3 Non VG3 p value
Age* 6.06 3.12 0.027† 2.43 6.15 0.006† 6.57 4.17 0.429†
Male 39 (60.0) 32 (53.3) 0.960 25 (55.5) 44 (55.0) 0.994 9 (60.0) 60 (54.5) 0.851
Aboriginal 5 (7.7) 15 (23.1) 0.017 14 (31.1) 6 (7.5) 0.001 1 (6.7) 19 (17.3) 0.500
Regional 6 (9.2) 14 (23.3) 0.0343 11 (24.4) 9 (11.2) 0.093 3 (20.0) 17 (15.5) 0.940
TOTAL 65 60 45 80 15 110
Values are numbers (%). *Geometric mean age in years. †p value based on arithmetic means.
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4.5%-42.8%). Despite attempts to optimise primer de-
sign, we acknowledge there are inefficiencies in our as-
says suggested by the requirement of a nested approach
and for some isolates alternate fHbp primers. It may
have been more prudent to utilise published porA, fetA
and fHbp primers. Additionally, although a longer fetA
sequence was obtained, the fetA variable region is within
our second PCR segment allowing determination of fetA
characterisation from this single PCR and sequence.
Finally, we recognise that MLST testing would have
allowed more precise genetic information to compare to
the worldwide meningococcal epidemiology, however
was not feasible due to labour and time constraints.
Conclusions
We sequenced porA, fetA and fHbp genes of 128 menin-
gococcal isolates from Western Australia over the period
2000–2011. We found several types predominate in our
population and there was an association of PorA P1.22,14-
16 and FHbp variant group 2 with younger age and abori-
ginality. We found the FHbp modular groups of the bi-
valent Pfizer and multicomponent Novartis vaccines
constitute 8.26% and 47.7% respectively of the examined
serogroup B isolates from the 11 year period, though this
supplies only a crude genotypic prediction of vaccine effi-
cacy not taking into account all vaccine antigens or their
levels of expression.
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